• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估姑息预后评分(PaP)和常规收集的临床数据对急性护理医院姑息治疗咨询服务转介患者的生存预后的作用。

Evaluation of the Palliative Prognostic Score (PaP) and routinely collected clinical data in prognostication of survival for patients referred to a palliative care consultation service in an acute care hospital.

机构信息

Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

出版信息

J Pain Symptom Manage. 2011 Sep;42(3):419-31. doi: 10.1016/j.jpainsymman.2010.12.013. Epub 2011 Apr 7.

DOI:10.1016/j.jpainsymman.2010.12.013
PMID:21477974
Abstract

CONTEXT

Patients, caregivers, and clinicians require high levels of information regarding prognosis when conditions are incurable.

OBJECTIVES

  1. To validate the Palliative Prognostic Score (PaP) and 2) to evaluate prognostic capacity of used clinical tools and the diagnosis of delirium, in a population referred to a palliative care consultation service at a Canadian acute care hospital.

METHODS

This was a prospective observational cohort study on survival prediction based on the PaP and routinely collected clinical data, including the Palliative Performance Scale (PPS) and the Folstein Mini-Mental State Examination (MMSE). Kaplan-Meier survival curves, log-rank tests for significant differences between survival curves, and the Cox proportional hazards model were used to identify the relationship between the hazard ratio for death and the above variables.

RESULTS

Nine hundred fifty-eight cases underwent final analysis, of which 181 (19%) had a noncancer diagnosis. Median and mean survival were 35 and 131 days, respectively. The three groups, divided based on different ranges of PaP, had significantly different survival curves, with 30-day-survival rates of 78%, 55%, and 11%. Age, PPS, and PaP remained significantly associated with survival, whereas diagnosis group, MMSE, and delirium became insignificant, despite lower hazard of death for cancer vs. noncancer and higher hazard for abnormal vs. normal MMSE and presence vs. absence of delirium.

CONCLUSION

The PaP was successfully validated in a population with characteristics that extend beyond those of the population in which it was originally developed. This is the largest sample in which the PaP has been validated to date.

摘要

背景

当疾病无法治愈时,患者、护理人员和临床医生需要大量有关预后的信息。

目的

1)验证姑息预后评分(PaP),2)评估在加拿大一家急性护理医院姑息治疗咨询服务中就诊的患者中,常用临床工具和谵妄诊断的预后能力。

方法

这是一项基于 PaP 和常规收集的临床数据(包括姑息治疗表现量表(PPS)和 Folstein 简易精神状态检查(MMSE))的生存预测的前瞻性观察队列研究。Kaplan-Meier 生存曲线、生存曲线之间差异的对数秩检验以及 Cox 比例风险模型用于识别死亡风险的危险比与上述变量之间的关系。

结果

958 例患者进行了最终分析,其中 181 例(19%)有非癌症诊断。中位和平均生存时间分别为 35 天和 131 天。根据 PaP 的不同范围分为三组,其生存曲线有显著差异,30 天生存率分别为 78%、55%和 11%。年龄、PPS 和 PaP 与生存仍显著相关,而诊断组、MMSE 和谵妄则变得不显著,尽管癌症与非癌症相比死亡风险较低,MMSE 异常与正常相比和谵妄存在与不存在相比死亡风险较高。

结论

在扩展了原始开发人群特征的人群中,成功验证了 PaP。这是迄今为止 PaP 验证的最大样本。

相似文献

1
Evaluation of the Palliative Prognostic Score (PaP) and routinely collected clinical data in prognostication of survival for patients referred to a palliative care consultation service in an acute care hospital.评估姑息预后评分(PaP)和常规收集的临床数据对急性护理医院姑息治疗咨询服务转介患者的生存预后的作用。
J Pain Symptom Manage. 2011 Sep;42(3):419-31. doi: 10.1016/j.jpainsymman.2010.12.013. Epub 2011 Apr 7.
2
Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model.现实世界中晚期癌症患者的生存预测:姑息预后评分、谵妄-姑息预后评分、姑息预后指数与姑息治疗研究预测模型中改良预后的比较
Eur J Cancer. 2015 Aug;51(12):1618-29. doi: 10.1016/j.ejca.2015.04.025. Epub 2015 Jun 11.
3
Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer.姑息性预后评分对晚期癌症住院患者的诊断准确性。
J Clin Oncol. 2004 Dec 1;22(23):4823-8. doi: 10.1200/JCO.2004.12.056.
4
Use of the Palliative Performance Scale (PPS) for end-of-life prognostication in a palliative medicine consultation service.在姑息医学咨询服务中使用姑息治疗表现量表(PPS)进行临终预后评估。
J Pain Symptom Manage. 2009 Jun;37(6):965-72. doi: 10.1016/j.jpainsymman.2008.08.003. Epub 2009 Feb 20.
5
Survival of women with cancer in palliative care: use of the palliative prognostic score in a population of Brazilian women.癌症晚期患者女性的生存状况:巴西女性人群中使用姑息预后评分。
J Pain Symptom Manage. 2010 Jan;39(1):69-75. doi: 10.1016/j.jpainsymman.2009.05.020.
6
Development of a predicting tool for survival of terminally ill cancer patients.开发一种预测终末期癌症患者生存情况的工具。
Jpn J Clin Oncol. 2010 May;40(5):442-8. doi: 10.1093/jjco/hyp182. Epub 2010 Jan 18.
7
A palliative prognostic score for terminally ill children and adolescents with cancer.癌症终末期儿童和青少年的姑息预后评分。
Pediatr Blood Cancer. 2010 Dec 1;55(6):1167-71. doi: 10.1002/pbc.22644.
8
Development and validation of a prognostic nomogram for terminally ill cancer patients.终末期癌症患者预后列线图的开发和验证。
J Natl Cancer Inst. 2011 Nov 2;103(21):1613-20. doi: 10.1093/jnci/djr388. Epub 2011 Oct 4.
9
Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium.终末期癌症患者的生存预测:修订包含谵妄的姑息预后评分。
Oncologist. 2011;16(12):1793-9. doi: 10.1634/theoncologist.2011-0130. Epub 2011 Oct 31.
10
Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.前列腺特异性抗原/前列腺酸性磷酸酶比值是IV期前列腺癌患者的重要预后因素。
Urology. 2007 Oct;70(4):702-5. doi: 10.1016/j.urology.2007.05.019.

引用本文的文献

1
Prognoses Associated With Palliative Performance Scale Scores in Modern Palliative Care Practice.在现代姑息治疗实践中,与姑息治疗表现量表评分相关的预后。
JAMA Netw Open. 2024 Jul 1;7(7):e2420472. doi: 10.1001/jamanetworkopen.2024.20472.
2
Palliative prognostic scores for survival prediction of cancer patients: a systematic review and meta-analysis.用于预测癌症患者生存预后的姑息预后评分:系统评价和荟萃分析。
J Natl Cancer Inst. 2024 Jun 7;116(6):829-857. doi: 10.1093/jnci/djae036.
3
Prevalence of Delirium in Advance Cancer Patients Admitted in Hospice Centre and Outcome after Palliative Intervention.
临终关怀中心收治的晚期癌症患者谵妄的患病率及姑息治疗干预后的结局
Indian J Palliat Care. 2023 Jan-Mar;29(1):82-88. doi: 10.25259/IJPC_114_2022. Epub 2022 Sep 7.
4
Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients.晚期癌症患者PaP评分列线图的开发与验证
Cancers (Basel). 2022 May 19;14(10):2510. doi: 10.3390/cancers14102510.
5
End-of-life care in cancer patients: how much drug therapy and how much palliative care? Record linkage study in Northern Italy.癌症患者的临终关怀:药物治疗和姑息治疗各占多少?意大利北部的记录链接研究。
BMJ Open. 2022 May 6;12(5):e057437. doi: 10.1136/bmjopen-2021-057437.
6
Deep-Learning Approach to Predict Survival Outcomes Using Wearable Actigraphy Device Among End-Stage Cancer Patients.基于可穿戴活动记录仪的深度学习方法预测终末期癌症患者的生存结局。
Front Public Health. 2021 Dec 9;9:730150. doi: 10.3389/fpubh.2021.730150. eCollection 2021.
7
Knowledge and use of prognostic scales by oncologists and palliative care physicians in adult patients with advanced cancer: A national survey (ONCOPRONO study).癌症晚期成年患者的肿瘤医生和姑息治疗医生对预后评分量表的认知和使用:一项全国性调查(ONCOPRONO 研究)。
Cancer Med. 2022 Feb;11(3):826-837. doi: 10.1002/cam4.4467. Epub 2021 Dec 24.
8
Outcome, demography and resource utilization in ICU Patients with delirium and malignancy.ICU 中合并谵妄和恶性肿瘤的患者的结局、人口统计学特征和资源利用情况。
Sci Rep. 2021 Sep 21;11(1):18756. doi: 10.1038/s41598-021-98200-8.
9
Prognostic models of survival in patients with advanced incurable cancer: the PiPS2 observational study.晚期不可治愈癌症患者生存预后模型:PiPS2 观察性研究。
Health Technol Assess. 2021 May;25(28):1-118. doi: 10.3310/hta25280.
10
Validation of the Palliative Prognostic Index, Performance Status-Based Palliative Prognostic Index and Chinese Prognostic Scale in a home palliative care setting for patients with advanced cancer in China.在中国的居家舒缓治疗环境中,验证舒缓预后指数、基于活动状态的舒缓预后指数和中国预后量表在晚期癌症患者中的应用。
BMC Palliat Care. 2020 Oct 31;19(1):167. doi: 10.1186/s12904-020-00676-0.